Evidence map›Paper›PMID 40273494›Full record

SynthesisClinics (Sao Paulo, Brazil)2025

A systematic review and meta-analysis of the efficacy and safety of glucocorticoids in the treatment of severe pneumonia.

Jingye Liu, Zhiqiang Yang

Abstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Clinics (Sao Paulo, Brazil), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jingye LiuEICU, Zhoushan Hospital, Zhejiang, China.
Zhiqiang YangDepartment of Respiratory and Critical Care Medicine, Zhoushan Hospital, Zhejiang, China. Electronic address: yangzhiqiang214@yeah.net.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo systematically evaluate the efficacy and superiority of glucocorticoids in the treatment of severe pneumonia.

methodRandomized Controlled Trials (RCTs) on glucocorticoids in the treatment of severe pneumonia were retrieved from CNKI, CBM, China Science and Technology Journal Database (VIP), Wanfang Database, and PubMed as of January 1, 2017. The literature was independently and objectively screened, extracted, and evaluated by two researchers, and a meta-analysis of the extracted data was performed using Revman 5.3 software.

resultsTen studies that met the inclusion criteria were included, with a cumulative total of 1120 cases. The meta-analysis results confirmed that the observation group was superior to the control group in terms of efficacy rate, temperature recovery time, cough relief time, rale disappearance time, and serum CRP level. There was no statistically significant difference in terms of the incidence of adverse reactions, mortality rate, and reinfection rate between the two groups.

conclusionsGlucocorticoids showed an obvious clinical efficacy in patients with severe pneumonia. However, due to the small number of included studies and the ambiguity of numerous bias risk assessments, high-quality and large-sample RCTs are still needed to provide corroborating evidence.

Indexed as

GlucocorticoidsPneumoniaHumansRandomized Controlled Trials as TopicSeverity of Illness IndexTreatment OutcomeGlucocorticoidsGlucocorticoidsMeta-analysisSerum CRPSevere pneumonia

Identifiers

PMID40273494
PMCPMC12051649

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.